SODIUM CHLORIDE - sodium chloride injection Fresenius Kabi USA, LLC

Sodium Chloride Injection, USP

0.9%

DESCRIPTION:

This preparation is designed solely for parenteral use only after addition of drugs that require dilution or must be dissolved in an aqueous vehicle prior to injection.

Sodium Chloride Injection, USP, 0.9% is a sterile, nonpyrogenic solution. The osmolarity is 0.300 mOsmol/mL (calculated).

Each mL contains: Sodium chloride 9 mg; Water for Injection q.s. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single dose containers. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (pH 4.5-7.0).

Sodium chloride occurs as colorless cubic crystals or white crystalline powder and has a saline taste. Sodium chloride is freely soluble in water. It is soluble in glycerin and slightly soluble in alcohol.

The empirical formula for sodium chloride is NaCl and the molecular weight is 58.44.

CLINICAL PHARMACOLOGY:

Sodium chloride in water dissociates to provide sodium (Na⁺) and chloride (Cl[—]) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance.

The distribution and excretion of sodium (Na⁺) and chloride (Cl[—]) are largely under the control of the kidney which maintains a balance between intake and output.

The small volume of fluid and amount of sodium chloride provided by Sodium Chloride Injection, USP, 0.9%, when used only as an isotonic vehicle for parenteral injection of drugs, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in neonates and very small infants.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na⁺) plays a major role in maintaining physiologic equilibrium.

INDICATIONS AND USAGE:

This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular, or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

PRECAUTIONS:

Consult the manufacturer's instructions for choice of vehicle, appropriate dilution or volume for dissolving the drugs to be injected, including the route and rate of injection. Inspect reconstituted (diluted or dissolved) drugs for clarity (if soluble) and freedom from unexpected precipitation or discoloration prior to administration.

Pregnancy

Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP, 0.9%. It is also not known whether Sodium Chloride Injection containing additives can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection, USP, 0.9% containing additives should be given to a pregnant woman only if clearly needed.

Pediatric Use

The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.

Drug Interactions

Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.

Use aseptic technique for single or multiple entry and withdrawal from all containers.

When diluting or dissolving drugs, mix thoroughly and use promptly.

Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.

Do not use unless the solution is clear and seal intact. Do not reuse single dose containers, discard unused portion.

ADVERSE REACTIONS:

Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures and, if possible, retrieve and save the remainder of the unused vehicle for examination.

OVERDOSAGE:

Use only as a diluent or solvent. This parenteral preparation is unlikely to pose a threat of carbohydrate, sodium chloride or fluid overload except possibly in neonates or very small infants. In the event these should occur, reevaluate the patient and institute appropriate corrective measures. (See **PRECAUTIONS** and **ADVERSE REACTIONS**).

DOSAGE AND ADMINISTRATION:

The volume of the preparation to be used for diluting or dissolving any drug for injection, is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacturer.

This parenteral should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See **PRECAUTIONS**.

HOW SUPPLIED:

Sodium Chloride Injection, USP, 0.9%, preservative free, is available as follows:

Product Code	Unit of Sale	Each
918602	63323-186-02	NDC 63323-186-04
	Unit of 25	2 mL fill, in a 3 mL
		Single Dose vial
918610	63323-186-10	NDC 63323-186-01
	Unit of 25	10 mL Single Dose vial
918620	63323-186-20	NDC 63323-186-03
	Unit of 25	20 mL Single Dose vial

Preservative Free. Discard unused portion.

Use only if solution is clear and seal intact.

Store at 20^o to 25^oC (68^o to 77^oF) [see USP Controlled Room Temperature]

FRESENIUS KABI

www.fresenius-kabi.com/us

45764F

Revised: November 2020

PACKAGE LABEL - PRINCIPAL DISPLAY - Sodium Chloride 2 mL Single Dose Vial Label

NDC 63323-186-04

918602

Sodium Chloride Injection, USP

0.9%


2 mL Single Dose Vial

FOR DRUG DILUENT USE

Preservative Free

Rx only

Discard unused portion.



PACKAGE LABEL - PRINCIPAL DISPLAY - Sodium Chloride 2 mL Single Dose Vial Tray Label

NDC 63323-186-02

918602

Sodium Chloride Injection, USP

0.9%

FOR DRUG DILUENT USE

Rx only

25 x 2 mL Single Dose Vials

NDC 63323-186-02 918602 Sodium Chloride Injection, USP	ic tion. Sodium ad/or n added insert. is clear is clear ontrolled	6023
0.9%	ogen Free Free d por mate clan C	318
FOR DRUG DILUENT USE	npyr ive live uused ontai; stave stave stave stave stave to to to to to to to to	32; = 8 = 6
Rx only	, No d un d un c c d un c c d d u c c d i c c c c c c c c c c c c c c c c	5 9
25 x 2 mL Single Dose Vials	Sterile Presen Discarr Each m for pH naOH r for pH Usual I Usual I Usual I Use on Use on and se Store a Room 7?*	Frese Lake Z(4 2 01)203

PACKAGE LABEL - PRINCIPAL DISPLAY - Sodium Chloride 10 mL Single Dose Vial Label

NDC 63323-186-01

918610

Sodium Chloride Injection, USP

0.9%

FOR DRUG DILUENT USE

Rx only

10 mL Single Dose Vial



PACKAGE LABEL - PRINCIPAL DISPLAY - Sodium Chloride 10 mL Single Dose Vial Tray Label

NDC 63323-186-10

918610

Sodium Chloride Injection, USP

0.9%

FOR DRUG DILUENT USE

Rx only

25 x 10 mL Single Dose Vials



PACKAGE LABEL - PRINCIPAL DISPLAY - Sodium Chloride 20 mL Single Dose Vial Label

I

NDC 63323-186-03

918620

Sodium Chloride Injection, USP

0.9%

FOR DRUG DILUENT USE

Rx only

20 mL Single Dose Vial



PACKAGE LABEL - PRINCIPAL DISPLAY - Sodium Chloride 20 mL Single Dose Vial Tray Label

NDC 63323-186-20

918620

Sodium Chloride Injection, USP

0.9%

FOR DRUG DILUENT USE

Rx only

25 x 20 mL Single Dose Vials

NDC 63323-186-20 918620		:bu		act.	Ire].			
Sodium Chloride Injection, USP		chloride 9 21 and/or ed for pH		and seal intact	⁺ to 77°F) Temperatu	sn/mo:		86207
0.9%	ic	tion. odium q.s. H(en add		insert s clear	C (68° Room	i 80047 (abi.c	48B	32318
FOR DRUG DILUENT USE	Nonpyrogenic rative Free	ed por ains: S sction we bee	mL	:: See ution is	to 25° trolled	Kabi , IL 6 nius-k	424	20363
Rx only	, Nonpy rvative	l unus L conti or Inje nay ha nent.	m0smol/I	Dosage: Ily if solut	t 20° P Con	reser		(01)2
25 x 20 mL Single Dose Vials	Sterile, Preser	Discarc Each m Water f NaOH n adjustn	0.3 m0	_	Store a [see US	Frese Lake <u>z</u> www.f		

I

Ρ									
	roduct Info	rmation							
Product Type			HUMAN PRESCRIPTION DRUG	Item Code (So	ltem Code (Source)				
Route of Administration			INTRAVENOUS						
A	Active Ingredient/Active Moiety								
		Ir	ngredient Name			isis of rength	Strength		
		DE (UNII: 451W47 NII:Q32ZN48698)	IQ8X) (SODIUM CATION - UNII:LYR4M0NH37,			SODIUM 9 m CHLORIDE in			
In	Inactive Ingredients								
		ACID (UNII: QTT:	Ingredient Name			Stre	ngth		
Packaging # Item Code Description Marketing Start Marketing End									
		_		Marketing	Start	Marke	tina End		
#	Item Code	Pa	ackage Description	Marketing Date			ting End Date		
	Item Code NDC:63323- 186-02	P a 25 in 1 TRAY	ackage Description	-			-		
1	NDC:63323-	25 in 1 TRAY	SINGLE-DOSE; Type 0: Not a	Date			-		
1	NDC:63323- 186-02 NDC:63323-	25 in 1 TRAY 2 mL in 1 VIAL, 9	SINGLE-DOSE; Type 0: Not a	Date			-		
1 1 2	NDC:63323- 186-02 NDC:63323- 186-04 NDC:63323-	25 in 1 TRAY 2 mL in 1 VIAL, 5 Combination Pro 25 in 1 TRAY	SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a	Date 08/10/2000			-		
1 1 2 2	NDC:63323- 186-02 NDC:63323- 186-04 NDC:63323- 186-10 NDC:63323-	25 in 1 TRAY 2 mL in 1 VIAL, 9 Combination Pro 25 in 1 TRAY 10 mL in 1 VIAL,	SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a	Date 08/10/2000			-		
1 1 2 2 3	NDC:63323- 186-02 NDC:63323- 186-04 NDC:63323- 186-10 NDC:63323- 186-01 NDC:63323-	25 in 1 TRAY 2 mL in 1 VIAL, 3 Combination Pro 25 in 1 TRAY 10 mL in 1 VIAL, Combination Pro 25 in 1 TRAY	SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a	Date 08/10/2000 08/10/2000			-		
1 1 2 2 3	NDC:63323- 186-02 NDC:63323- 186-04 NDC:63323- 186-10 NDC:63323- 186-01 NDC:63323- 186-20 NDC:63323-	25 in 1 TRAY 2 mL in 1 VIAL, 3 Combination Pro 25 in 1 TRAY 10 mL in 1 VIAL, Combination Pro 25 in 1 TRAY 20 mL in 1 VIAL,	SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a	Date 08/10/2000 08/10/2000			-		
1 1 2 2 3 3	NDC:63323- 186-02 NDC:63323- 186-04 NDC:63323- 186-10 NDC:63323- 186-01 NDC:63323- 186-20 NDC:63323- 186-03	25 in 1 TRAY 2 mL in 1 VIAL, 3 Combination Pro 25 in 1 TRAY 10 mL in 1 VIAL, Combination Pro 25 in 1 TRAY 20 mL in 1 VIAL,	SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a oduct	Date 08/10/2000 08/10/2000			-		
1 1 2 2 3 3	NDC:63323- 186-02 NDC:63323- 186-04 NDC:63323- 186-10 NDC:63323- 186-01 NDC:63323- 186-20 NDC:63323- 186-03	25 in 1 TRAY 2 mL in 1 VIAL, 2 Combination Pro 25 in 1 TRAY 10 mL in 1 VIAL, Combination Pro 25 in 1 TRAY 20 mL in 1 VIAL, Combination Pro Informat	SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a oduct SINGLE-DOSE; Type 0: Not a oduct	Date 08/10/2000 08/10/2000		Marke	-		

Labeler - Fresenius Kabi USA, LLC (608775388)

Establishment						
Name	Address	ID/FEI	Business Operations			
Fresenius Kabi USA, LLC		840771732	manufacture(63323-186) , analysis(63323-186)			